Omniab, Inc. · NASDAQ:OABI
Omniab — Q1 2025 Earnings Presentation
26 slides from Omniab's earnings presentation, May 8, 2025
Slide 1: Q1 2025 Financial Results & Business Update
1 Q1 2025 Financial Results & Business Update Nasdaq: OABI May 8, 2025
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance fo
Slide 3: Introduction - Matt Foehr
Omni Introduction - Matt Foehr
Slide 4: Q1 2025 Highlights
4 Q1 2025 Highlights Our outlook for 2025 remains on-track Strong deal-flow to start the year, with platform and recent asset-based transactions Partner pipeline progression continues Launch of xPloration® to our partners expected to be accretive to our business
Slide 5: Active Partners
5 Active Partners Q1 2025: 95 ACTIVE PARTNERS Number of Active Partners 100 95 • We continue to grow and diversify our partnership base, with 95 Active Partners as of 3/31/2025 50 • New licenses added in Q1 include those with Wyss Institute at Harvard, Takis Biotech S.r.l., and Orion Corporation 0 S
Slide 6: Active Programs
6 Active Programs Q1 2025: 378 ACTIVE PROGRAMS Q1 2025 Change in Number of Active Programs Active Programs 400 31 378 378 363 • 378 Active Programs as of 3/31/2025 (16) • Momentum of additions from Q4 2024 continued in Q1 2025 200 • >98% of our Active Programs have contracted future economics to Omn
Slide 7: Active Clinical Programs and Approved Products
7 Active Clinical Programs and Approved Products 45 Number of Active Clinical Programs and Approved Products(1)(2) 33 • 33 active clinical programs and approved products as of 3/31/2025 30 • One new OmniAb-derived program entered a first-in-human clinical trial in Q1 ‒ Genmab’s GEN1078 first-in-huma
Slide 8: Post-Discovery Stage Programs
8 Post-Discovery Stage Programs 39% GROWTH OVER THE LAST 24 MONTHS As of 3/31/2023 As of 3/31/2024 As of 3/31/2025 Registration: 1 Approved: 3 Registration: 1 Approved: 3 Approved: 3 Phase 3: 2 Phase 3: 1 Phase 3: 5 Preclinical: 14 Phase 2: 2 Phase 2: 2 Preclinical: 18 Preclinical: 24 Phase 2: 3 Pha
Slide 9: Select Partner Updates
9 Select Partner Updates IMVT-1402 Sugemalimab PF-08046049 (BB228) M9140 FcRn PD-L1 CD228 x 4-1BB CEACAM-5 Immunovant announced that potentially CStone Pharmaceuticals announced the Pfizer presented preclinical data at the Merck KGaA presented the PROCEADE registrational trials for IMVT-1402 are sub
Slide 10: Introducing the xPloration Partner Access Program
10 Introducing the xPloration Partner Access Program • xPloration is a highly leverageable technology ‒ Seamlessly integrates with our antibody creation/source technologies ‒ Ability to significantly enhance our partners' capabilities in antibody discovery and screening, potentially enabling more Om
Slide 11: xPloration - Bob Chen
Omni xPloration Bob Chen
Slide 12: Introducing the xPloration Partner Access Program
12 Introducing the xPloration Partner Access Program DRIVING GROWTH THROUGH OFFERING TECHNOLOGY TO OMNIAB PARTNERS FOR USE IN THEIR OWN LABORATORIES Empowering our partners • The substantial value of xPloration-based screening has been recognized by our partners Matured and validated technology • Re
Slide 13: xPloration: AI-Driven Deep Functional Screening
13 xPloration: AI-Driven Deep Functional Screening 1 | Load the chip 2 | Analyze with Machine Vision 3 | Recover hits with laser 1.5 million, 40 µm microcapillaries Automated imaging Precise laser-based recovery Unique through-hole format Computer vision hit detection Single-cell barcoding or pooled
Slide 14: Technical Differentiation of xPloration
14 Technical Differentiation of xPloration INNOVATIVE, HIGH-THROUGHPUT SINGLE B-CELL PLATFORM THAT LEVERAGES ARTIFICIAL INTELLIGENCE – EXPANDS SINGLE CELL SCREENING CAPABILITIES AND SIMPLIFIES WORKFLOWS Fast and powerful • Rapid instrument run times of approximately 1.5 hours ‒ Short run times enabl
Slide 15: Now available through Partner Access Program
15 Now available through Partner Access Program PLATFORM OFFERING INCLUDES: • Furthers OmniAb’s mission of pushing the frontiers COMPETITIVELY-PRICED INSTRUMENT of discovery technologies PROPRIETARY, SINGLE-USE CONSUMABLES • Leverages our ecosystem of partners and adds to ANNUAL SUBSCRIPTION SERVICE
Slide 16: Upcoming Scientific Presentations
16 Upcoming Scientific Presentations EXPANDING THE VISIBILITY AND REACH OF OUR PLATFORM May 13th June 10th Boston Basel, Switzerland xPloration: Simplifying Deep Antibody Mining for Maximum Building Multispecifics from in vivo-Derived Impact Antibody Domains and Alternative Scaffolds Christel Ifflan
Slide 17: Financial Updates
17 Financial Updates Kurt Gustafson
Slide 18: Q1 2025 Revenue
18 Q1 2025 Revenue $ in millions $4.2 • Q1 2025 Revenue increased as compared to Q1 2024 $4 $3.8 License & Milestone Revenue License & Milestone • The increase was primarily driven by License and $3 Revenue Milestone revenue, which included the achievement of a Phase 1 milestone for GEN1078 $2 Servi
Slide 19: Q1 2025 Operating Expense
19 Q1 2025 Operating Expense $ in millions $26.4 $25 • Operating expense lower than prior year period Other $23.0 Other $20 • Research and Development expense decreased G&A primarily due to lower stock-based compensation G&A expense and lower external expenses associated $15 with small-molecule ion
Slide 20: Q1 2025 vs. Q1 2024 Financial Results
20 Q1 2025 vs. Q1 2024 Financial Results (in millions, except per share data) Q1 2024 Q1 2025 Variance License and milestone revenue $ 0.7 $ 2.0 $ 1.3 Service revenue 2.8 1.9 (0.8) Royalty revenue 0.3 0.2 (0.1) Total revenue 3.8 4.2 0.4 Research & development 14.6 12.6 (1.9) General & administrative
Slide 21: Balance Sheet
21 Balance Sheet (in millions) December 31, March 31, 2024 2025 ASSETS Current assets: Cash & investments $ 59.4 $ 43.6 Accounts receivable, net 5.3 6.5 Other current assets 3.4 3.5 Goodwill & intangible assets 222.0 218.8 PPE & leases 33.3 32.0 Other assets 2.1 1.8 Total assets $ 325.6 $ 306.2 LIAB
Slide 22: 2025 Guidance
22 2025 Guidance • Affirming revenue guidance - expected to be $20 million to $25 million • Operating expense guidance revised to be in the range of $85 to $90 million from previous guidance of $90 million to $95 million • 2025 cash use expected to be lower than cash use in 2024(1) • 2025 effective
Slide 23: Q&A
Omni Q&A
Slide 24: Clinical and Commercial-Stage Partner Pipeline
Clinical and Commercial-Stage Partner Pipeline 24 (1)(2) AS OF 3/31/2025 ONLY PROGRAMS WITH DOWNSTREAM ECONOMICS ARE SHOWN Phase 1 Phase 2 Phase 3 Registration Approved Johnson & Johnson Aptevo Therapeutics CCTQ Pharma Hanall Biopharma, Hanall Biopharma, Immunovant Genmab Gloria Biosciences, Arcus B
Slide 25: Selected Partner Clinical Presentations at ASCO
25 Selected Partner Clinical Presentations at ASCO ASCO ANNUAL MEETING IS TAKING PLACE MAY 30TH TO JUNE 3RD JNJ-79635322 BCMA x GPRC5D x CD3 First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific Zimberelimab antibody (TsAb), in patients (pts) with relapsed/refractory
Slide 26: Omni
Omni >